Off with the label and on the Avastin bandwagon: why now and how far?
Santhan Gopal
K S
KS
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004345:Drug Industry; D004992:Ethics, Medical; D006801:Humans; D007194:India; D056687:Off-Label Use / Q000941:ethics / Q000331:legislation & jurisprudence; D009885:Ophthalmology / Q000379:methods*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab